GO
Loading...

Enter multiple symbols separated by commas

Biogen Inc

More

  • Street picks: 10 stocks ready to pop Thursday, 30 Apr 2015 | 7:00 AM ET

    More than half of the S&P 500 is projected to rise by 8 percent in 12 months, according to analysts. Here are the stocks that could rise the most.

  • Final Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 6:14 PM ET

    Amgen Inc. fell $1.51 or. 9 percent, to $160.98. Biogen Idec rose $9.10 or 2.4 percent, to $383.78. Celgene Corp. fell$. 32 or. 3 percent, to $113.20.

  • Midday Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 2:53 PM ET

    Amgen Inc. fell $1.39 or. 9 percent, to $161.10. Biogen Idec rose $8.25 or 2.2 percent, to $382.93. Celgene Corp. fell$. 69 or. 6 percent, to $112.83.

  • Early Glance: Biotechnology companies Wednesday, 29 Apr 2015 | 10:45 AM ET

    Amgen Inc. rose$. 60 or. 4 percent, to $163.09. Biogen Idec rose $9.40 or 2.5 percent, to $384.08. Celgene Corp. rose$. 30 or. 3 percent, to $113.82.

  • Final Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 6:04 PM ET

    Amgen Inc. rose$. 11 or. 1 percent, to $162.49. Biogen Idec fell $14.59 or 3.7 percent, to $374.68. Celgene Corp. fell $1.20 or 1.0 percent, to $113.52.

  • Biogen takes on Alzheimer's   Tuesday, 28 Apr 2015 | 4:29 PM ET
    alzheimer's

    George Scangos, Biogen CEO, discusses progress in clinical trials for Alzheimer's treatments, and the outlook for its multiple sclerosis Tecfidera drug.

  • Midday Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 1:50 PM ET

    Amgen Inc. rose $2.04 or 1.3 percent, to $164.42. Biogen Idec fell $8.05 or 2.1 percent, to $381.22. Celgene Corp. fell$. 81 or. 7 percent, to $113.91.

  • Early Glance: Biotechnology companies Tuesday, 28 Apr 2015 | 10:39 AM ET

    Amgen Inc. fell$. 23 or. 1 percent, to $162.15. Biogen Idec fell $8.74 or 2.2 percent, to $380.53. Celgene Corp. fell $1.03 or. 9 percent, to $113.69.

  • Final Glance: Biotechnology companies Monday, 27 Apr 2015 | 6:06 PM ET

    Amgen Inc. fell $5.53 or 3.3 percent, to $162.38. Biogen Idec fell $12.44 or 3.1 percent, to $389.27. Celgene Corp. fell $4.00 or 3.4 percent, to $114.72.

  • Biotechs stick it to stocks Monday, 27 Apr 2015 | 4:30 PM ET
    Medical injection

    Biotech is getting roughed up, after leading the market's gains this year.

  • What's wrong with healthcare and biotech? Monday, 27 Apr 2015 | 3:32 PM ET
    Traders work on the floor of the New York Stock Exchange.

    Biotech, which has been a market leader all year, is weak, with both the market-cap weighted IBB and equal weighted XBI down roughly 4 percent each.

  • Midday Glance: Biotechnology companies Monday, 27 Apr 2015 | 1:50 PM ET

    Amgen Inc. fell $5.07 or 3.0 percent, to $162.84. Biogen Idec fell $11.37 or 2.8 percent, to $390.34. Celgene Corp. fell $3.51 or 3.0 percent, to $115.20.

  • Early Glance: Biotechnology companies Monday, 27 Apr 2015 | 11:25 AM ET

    Amgen Inc. fell $1.08 or. 6 percent, to $166.83. Biogen Idec fell $1.10 or. 3 percent, to $400.62. Celgene Corp. fell$. 50 or. 4 percent, to $118.21.

  • Final Glance: Biotechnology companies Friday, 24 Apr 2015 | 8:08 PM ET

    Amgen Inc. fell $1.26 or. 7 percent, to $167.91. Biogen Idec fell $28.57 or 6.6 percent, to $401.71. Celgene Corp. rose $2.62 or 2.3 percent, to $118.71.

  • Xerox and Amazon are big market movers Friday, 24 Apr 2015 | 4:34 PM ET

    NEW YORK— Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:. Xerox Corp., down $1.15 to $11.99. Rival Comcast dropped its $45 billion buyout bid for the cable company after pushback from the Federal Communications Commission.

  • Traders work on the floor of the New York Stock Exchange.

    U.S. stocks closed higher on Friday, with the Nasdaq setting another record as investors cheered major earnings reports.

  • Midday Glance: Biotechnology companies Friday, 24 Apr 2015 | 1:36 PM ET

    Amgen Inc. fell $1.01 or. 6 percent, to $168.16. Biogen Idec fell $25.40 or 5.9 percent, to $404.88. Celgene Corp. rose $3.05 or 2.6 percent, to $119.14.

  • April 24- Slowing sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera and a delay in a data readout for its keenly watched Alzheimer's drug sent the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued forecast, Chief...

  • Early Glance: Biotechnology companies Friday, 24 Apr 2015 | 10:55 AM ET

    Amgen Inc. fell $1.09 or. 6 percent, to $168.08. Biogen Idec fell $26.23 or 6.1 percent, to $404.05. Celgene Corp. rose$. 79 or. 7 percent, to $116.88.

  • April 24- Sales of Biogen Inc's key oral multiple sclerosis drug Tecfidera fell on a sequential basis in the first quarter for the first time since its launch in 2013, sending the company's stock down as much as 8 percent on Friday. If Tecfidera's U.S. trajectory does not improve, Biogen's revenue growth may come in at the lower end of its previously issued...